The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits

Atherosclerosis

Volumn 127, Issue 1, 1996, Pages 123-129

  Sugano, Masahiro ^a   Makino, Naoki ^a   Yanaga, Takashi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

angiotensin II receptor antagonist; angiotensin converting enzyme inhibitor; atherosclerosis; E 4177; enalapril

Indexed keywords

4' [(2 CYCLOPROPYL 7 METHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL][1,1' BIPHENYL] 2 CARBOXYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RABBIT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA; ARTERIOSCLEROSIS; CELL DIVISION; CHOLESTEROL; CHOLESTEROL, DIETARY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENALAPRIL; IMIDAZOLES; LIPOPROTEINS; OLIGONUCLEOTIDE PROBES; POLYMERASE CHAIN REACTION; PYRIDINES; RABBITS; RANDOM ALLOCATION; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; SPECTROPHOTOMETRY;

EID: 0030588595     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)05942-4     Document Type: Article

References (29)

1. [1] Levy BI, Safar ME. Remodelling of the vascular system in response to hypertension and drug therapy. Clin Exp Pharmacol Physiol 1992;19 (Suppl.):33.
2. [2] Munro JM, Cotran RS. Biology of disease. The pathogenesis of atherogenesis: atherogenesis and inflammation. Lab Invest 1988;58:249.
3. [3] Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327.
4. [4] Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990;15(Suppl. 5):S65.
5. [5] Campbell JH, Fennesy P, Campbell CC. Effect of perindopril on the development of atherosclerosis in the cholesterol-fed rabbits. Clin Exp Pharmacol Physiol 1992;19(Suppl. 19): 13.
6. [6] Fennessy PA, Campbell JH, Campbell GR. Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. Atherosclerosis 1994;106:29.
7. [7] Riezebos J, Vleeming W, Beems RB, van Amsterdam JGC, Meijer GW, de Wildt DJ, Porsius AJ, Wemer J. Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: II. Effect on regression of atherosclerosis and restoration of endothelial function. J Cardiovasc Pharmacol 1994;23:424.
8. [8] Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450.
9. [9] Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens 1991;9:3.
10. [10] Ujhelyi MR, Ferguson RK, Vlasses PH. Angiotensin converting enzyme inhibitors: mechanistic controversies. Pharmacotherapy 1989;9:351.
11. [11] Schror K. Converting enzyme inhibitors and the interaction between kinins and eicosanoids. J Cardiovasc Pharmacol 1990;15(Suppl. 6):S60.
12. [12] Swartz SL. The role of prostaglandins in mediating the effects of angiotensin converting enzyme inhibitors and other antihypertensive drugs. Cardiovasc Drugs Ther 1987;1:39.
13. [13] Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH. Differential effects of renin-angiotensin system blockade on atherosclerosis in cholesterol-fed rabbits. J Clin Invest 1993;91:1453.
14. [14] Okunishi H, Song K, Oka Y, Kobayashi T, Kawamoto T, Ishikawa H, Mori N, Miyazaki M. In vitro pharmacology of a novel non-peptide angiotensin II-receptor antagonist, E-4177. Jpn J Pharmacol 1993;62:239.
15. [15] Carroll RM, Rudel LL. Lipoprotein separation and low density lipoprotein molecular weight determination using high performance gel-filtration chromatography. J Lipid Res 1983;24:200.
16. [16] Hayakari M, Kondo Y, Izumi H. A rapid and simple spectrophotometric assay of angiotensin-converting enzyme. Anal Biochem 1978;84:361.
17. [17] Makino N, Hata T, Sugano M, Dixon IMC, Yanaga T. Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type 1 receptor in rats. J Mol Cell Cardiol 1996;28:507
18. [18] Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186.
19. [19] Johnston CI, Jandeleit K, Mooser V, Katapothis K, Perich R, Paxton D, Murohara Y, Jackson B. Angiotensin-converting enzyme and its inhibition in the heart and blood vessels. J Cardiovasc Pharmacol 1992;20(Suppl B):S6.
20. [20] Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1989;62:749.
21. [21] Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 1994;107 (1):71.
22. [22] Nielsen LB, Stender S, Kjeldsen K, Nordestgaard BG. Effect of angiotensin II and enalapril on transfer of low-density lipoprotein into aortic intima in rabbits. Circ Res 1994;75:63.
23. [23] Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, Kaneda Y, Ogihara T, Dzau VJ. Evidence for direct local effect of angiotensin in vascular hypertrophy: in vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1994;94:978.
24. [24] Oparil S, Haber E. The renin angiotensin system. N Engl J Med 1974;291:389, 446.
25. [25] Schunkert H, Ingelfinger JR, Hirsch AT, Pinto Y, Remme WJ, Jacob H, Dzau VJ. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ Res 1993;72:312.
26. [26] Sugano M, Nakashima Y, Matsushima T, Takahara K, Takasugi M, Kuroiwa A, Koide A. Suppression of atherosclerosis in cholesterol-fed rabbits by diltiazem injection. Arterosclerosis 1986;6:237.
27. [27] Herbert JM, Delisee C, Dol F, Schaeffer P, Cazaubon C, Nisato D, Chatelain P. Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994;251(2-3):143.
28. [28] Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Ishimura Y, Chatani F, Iwao H. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 1995;273(1):509.
29. [29] Wong PC, Hart SD, Zaspel AM, Chiu AT, Ardecky RJ, Smith RD, Timmermans PBMWM. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: Dup 753 (Ang II-1) and PD123177 (Ang II-2). J Phamacol Exp Ther 1990;255:584.